In the last trading session, 8.27 million Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares changed hands as the company’s beta touched 1.02. With the company’s per share price at $3.59 changed hands at $0.07 or 1.99% during last session, the market valuation stood at $1.18B. IOVA’s last price was a discount, traded about -342.9% off its 52-week high of $15.90. The share price had its 52-week low at $3.50, which suggests the last value was 2.51% up since then. When we look at Iovance Biotherapeutics Inc’s average trading volume, we note the 10-day average is 11.11 million shares, with the 3-month average coming to 9.48 million.
Analysts gave the Iovance Biotherapeutics Inc (IOVA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended IOVA as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Iovance Biotherapeutics Inc’s EPS for the current quarter is expected to be -0.24.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Instantly IOVA was in green as seen at the end of in last trading. With action -4.27%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -51.49%, with the 5-day performance at -4.27% in the red. However, in the 30-day time frame, Iovance Biotherapeutics Inc (NASDAQ:IOVA) is -32.77% down. Looking at the short shares, we see there were 59.59 million shares sold at short interest cover period of 6.16 days.
The consensus price target for the stock as assigned by Wall Street analysts is 11.5, meaning bulls need an upside of 68.78% from its current market value. According to analyst projections, IOVA’s forecast low is 6 with 17 as the target high. To hit the forecast high, the stock’s price needs a -373.54% plunge from its current level, while the stock would need to soar -67.13% for it to hit the projected low.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
Year-over-year growth is forecast to reach 173.66% up from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 83.36M. 12 analysts are of the opinion that Iovance Biotherapeutics Inc’s revenue for the current quarter will be 102.38M. The company’s revenue for the corresponding quarters a year ago was 715k and 31.11M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 11,558.67%. The estimates for the next quarter sales put growth at 229.13%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 4.17%. The 2025 estimates are for Iovance Biotherapeutics Inc earnings to increase by 37.40%.
IOVA Dividends
Iovance Biotherapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.62% of Iovance Biotherapeutics Inc shares while 83.99% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 84.52%. There are 83.99% institutions holding the Iovance Biotherapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 9.7478% of the shares, roughly 25.95 million IOVA shares worth $208.12 million.
PERCEPTIVE ADVISORS LLC holds the second largest percentage of outstanding shares, with 9.1052% or 25.93 million shares worth $207.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 8.61 shares estimated at $30.91 million under it, the former controlled 2.63% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.25% of the shares, roughly 7.38 shares worth around $26.5 million.
